Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-α Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Barffour MA, Karanja E, Gandhi M, Kais SS, Kapur S, Ghouri YA.

Open source

DOI
10.3390/clinpract16070124
Published
2026-07-02
Container
Clin Pract
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/clinpract16070124,
  title = {Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-α Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.},
  author = {Barffour MA and  Karanja E and  Gandhi M and  Kais SS and  Kapur S and  Ghouri YA.},
  year = {2026},
  journal = {Clin Pract},
  doi = {10.3390/clinpract16070124},
  url = {https://doi.org/10.3390/clinpract16070124}
}

RIS

TY  - JOUR
TI  - Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-α Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
AU  - Barffour MA
AU  -  Karanja E
AU  -  Gandhi M
AU  -  Kais SS
AU  -  Kapur S
AU  -  Ghouri YA.
PY  - 2026
JO  - Clin Pract
DO  - 10.3390/clinpract16070124
UR  - https://doi.org/10.3390/clinpract16070124
ER  - 

APA

MA, B., E, K., M, G., SS, K., S, K., & YA., G. (2026). Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-α Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.. Clin Pract. https://doi.org/10.3390/clinpract16070124

Source records